CAMP4 Therapeutics Corporation Common Stock (CAMP) Stock Price

CAMPStock

$3.17+1.93%52W

Market Cap$198.93M

P/E—

PEG Ratio—

Div yield—

Beta-24.30

CAMP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-39.77%

Price vs S&P 500 (4W)-22.66%

VGM Score46.39

Book Value / Share (Quarterly)$0.60

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-2.86%

Cash Flow / Share (Quarterly)$-0.55

Price vs S&P 500 (YTD)-60.21%

Gross Margin (TTM)35.78%

Net Profit Margin (TTM)-7.27%

EPS (TTM)$-2.20

10-Day Avg Trading Volume0.25M

EPS Excl Extra (TTM)$-2.20

Revenue Growth (5Y)-4.22%

EPS (Annual)$-2.65

ROI (Annual)-168.55%

Gross Margin (Annual)36.96%

Net Profit Margin (5Y Avg)-7.07%

Cash / Share (Quarterly)$1.66

Revenue Growth QoQ (YoY)-15.26%

ROA (Last FY)-68.25%

Revenue Growth TTM (YoY)5.57%

EBITD / Share (TTM)$-1.04

ROE (5Y Avg)-18.64%

Operating Margin (TTM)-5.42%

Cash Flow / Share (Annual)$-0.57

P/B Ratio6.44x

P/B Ratio (Quarterly)7.41x

Net Income / Employee (Annual)$-1,675,100

Net Interest Coverage (TTM)-1.91x

ROA (TTM)-106.42%

EPS Incl Extra (Annual)$-2.65

Current Ratio (Annual)7.35x

Quick Ratio (Quarterly)4.69x

3-Month Avg Trading Volume0.28M

52-Week Price Return1.93%

Revenue / Employee (TTM)$450,310,600,000

Tangible BV / Share (Quarterly)$-2.90

P/S Ratio (Annual)0.05x

Asset Turnover (Annual)0.76x

52-Week High$7.75

Operating Margin (5Y Avg)-1.59%

EPS Excl Extra (Annual)$-2.65

CapEx CAGR (5Y)5.89%

26-Week Price Return-29.87%

Quick Ratio (Annual)7.31x

13-Week Price Return-14.56%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.70x

Enterprise Value$112.53M

Revenue / Share Growth (5Y)-4.22%

Asset Turnover (TTM)0.79x

Book Value / Share Growth (5Y)-41.47%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)8.82x

Pretax Margin (Annual)-10.63%

Cash / Share (Annual)$2.11

3-Month Return Std Dev99.08%

Gross Margin (5Y Avg)39.45%

Net Income / Employee (TTM)$-2,234,300

EBITDA CAGR (5Y)-30.38%

EBITDA Interim CAGR (5Y)-22.29%

ROE (Last FY)-168.55%

Net Interest Coverage (Annual)-0.98x

EPS Basic Excl Extra (Annual)$-2.65

Receivables Turnover (TTM)3.97x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.20

Receivables Turnover (Annual)4.08x

ROI (TTM)-194.57%

P/S Ratio (TTM)0.05x

Pretax Margin (5Y Avg)-5.59%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$-2.85

Free OCF CAGR (5Y)8.13%

Price vs S&P 500 (52W)-13.60%

EPS Growth TTM (YoY)47.80%

Year-to-Date Return-48.29%

5-Day Price Return-13.39%

EPS Normalized (Annual)$-2.65

ROA (5Y Avg)-4.61%

Net Profit Margin (Annual)-11.02%

Month-to-Date Return-21.53%

Cash Flow / Share (TTM)$0.03

EBITD / Share (Annual)$-1.68

Operating Margin (Annual)-8.83%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-5.86%

LT Debt / Equity (Quarterly)2157.89x

EPS Basic Excl Extra (TTM)$-2.20

P/B Ratio (Annual)6.67x

Inventory Turnover (TTM)7.17x

Pretax Margin (TTM)-6.83%

Book Value / Share (Annual)$0.92

Price vs S&P 500 (13W)-17.24%

Beta-24.30x

Revenue / Share (TTM)$7.92

ROE (TTM)-194.74%

52-Week Low$2.86

gGradeC

mGradeC

vgmGradeC

CAMP Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.21	-$0.22	-1.47%(-$0.00)
Q1 2026	May 7, 2026	-$0.21	-$0.21	-1.42%(-$0.00)
Q4 2025	Mar 5, 2026	-$0.29	-$0.23	+21.68%(+$0.06)
Q3 2025	Nov 6, 2025	-$0.48	-$0.54	-11.88%(-$0.06)
Q2 2025	Aug 14, 2025	-$0.67	-$0.62	+7.81%(+$0.05)

CAMP Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.25

4.31

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
CAMPCAMP4 Therapeutics Corporation Common Stock	—	C	C	0.0x	5.6%	35.8%	—	$3.17
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About CAMP4 Therapeutics Corporation Common Stock

Camp4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-based therapeutics to restore protein levels in genetic diseases of the central nervous system and liver. The company's pipeline includes two lead programs, CMP-CPS-001 and CMP-SYNGAP.

CAMP Insider Transactions

BuyAug 31, 2026
GOLD KELLY
Chief Financial Officer
Shares: 10,000Value: $39,600
SellAug 27, 2026
SCHWAB ANDREW J.
Director
Shares: 400,000Value: $1.62M
SellAug 24, 2026
SCHWAB ANDREW J.
Director
Shares: 10Value: $45
SellAug 21, 2026
SCHWAB ANDREW J.
Director
Shares: 191,865Value: $879,719
SellAug 19, 2026
TARDIFF DANIEL
Officer
Shares: 1,738Value: $8,273

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

LXEOLexeo Therapeutics, Inc. Common StockBiological Products
FATEFate Therapeutics, Inc.Biological Products
PLXProtalix BioTherapeutics, Inc. Common StockBiological Products
ALECAlector, Inc. Common StockBiological Products
NAGENiagen Bioscience, Inc. Common StockPharmaceutical Preparations
CGENCompugen LtdBiological Products
LTBRLightbridge Corp.Industrial Chemicals
IVVDInvivyd, Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$2.86

High$7.75